Eleanore Alexander1, Emma E McGinty2, Nae-Yuh Wang3, Arlene Dalcin4, Gerald J Jerome5, Edgar R Miller4, Faith Dickerson6, Jeanne Charleston4, Deborah R Young7, Joseph V Gennusa8, Stacy Goldsholl8, Courtney Cook9, Lawrence J Appel9, Gail L Daumit4. 1. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States. Electronic address: ealexa12@jhmi.edu. 2. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States. 3. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medicine, Baltimore, MD, 21205, United States. 4. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medicine, Baltimore, MD, 21205, United States. 5. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States; Department of Kinesiology, Towson University, Baltimore, MD, 21252, United States. 6. Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD 21204, United States. 7. Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 91024, United States. 8. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States. 9. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medicine, Baltimore, MD, 21205, United States.
Abstract
BACKGROUND:Persons with serious mental illnesses (SMI) such as schizophrenia and bipolar disorder have an increased risk of obesity and related chronic diseases and die 10-20years earlier than the overall population, primarily due to cardiovascular disease. In the ACHIEVE trial, a behavioural weight loss intervention led to clinically significant weight loss in persons with SMI. As the field turns its attention to intervention scale-up, it is important to understand whether the effectiveness of behavioural weight loss interventions for people with SMI, like ACHIEVE, differ for specific subgroups. METHODS: This study examined whether the effectiveness of the ACHIEVE intervention differed by participant characteristics (e.g. age, sex, race, psychiatric diagnosis, body mass index) and/or their weight-related attitudes and behaviours (e.g. eating, food preparation, and shopping habits). We used likelihood-based mixed effects models to examine whether the baseline to 18 month effects of the ACHIEVE intervention differed across subgroups. RESULTS: No statistically significant differences were found in the effectiveness of the ACHIEVE intervention across any of the subgroups examined. CONCLUSIONS: These findings suggest that the ACHIEVE behavioural weight loss intervention is broadly applicable to the diverse population of individuals with SMI.
RCT Entities:
BACKGROUND:Persons with serious mental illnesses (SMI) such as schizophrenia and bipolar disorder have an increased risk of obesity and related chronic diseases and die 10-20years earlier than the overall population, primarily due to cardiovascular disease. In the ACHIEVE trial, a behavioural weight loss intervention led to clinically significant weight loss in persons with SMI. As the field turns its attention to intervention scale-up, it is important to understand whether the effectiveness of behavioural weight loss interventions for people with SMI, like ACHIEVE, differ for specific subgroups. METHODS: This study examined whether the effectiveness of the ACHIEVE intervention differed by participant characteristics (e.g. age, sex, race, psychiatric diagnosis, body mass index) and/or their weight-related attitudes and behaviours (e.g. eating, food preparation, and shopping habits). We used likelihood-based mixed effects models to examine whether the baseline to 18 month effects of the ACHIEVE intervention differed across subgroups. RESULTS: No statistically significant differences were found in the effectiveness of the ACHIEVE intervention across any of the subgroups examined. CONCLUSIONS: These findings suggest that the ACHIEVE behavioural weight loss intervention is broadly applicable to the diverse population of individuals with SMI.
Authors: Gail L Daumit; Richard W Goldberg; Christopher Anthony; Faith Dickerson; Clayton H Brown; Julie Kreyenbuhl; Karen Wohlheiter; Lisa B Dixon Journal: J Nerv Ment Dis Date: 2005-10 Impact factor: 2.254
Authors: Eva Tseng; Arlene T Dalcin; Gerald J Jerome; Joseph V Gennusa; Stacy Goldsholl; Courtney Cook; Lawrence J Appel; Nisa M Maruthur; Gail L Daumit; Nae-Yuh Wang Journal: Diabetes Care Date: 2019-02-14 Impact factor: 19.112
Authors: Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit Journal: Gen Hosp Psychiatry Date: 2015-03-14 Impact factor: 3.238
Authors: Thomas A Wadden; Delia S West; Rebecca H Neiberg; Rena R Wing; Donna H Ryan; Karen C Johnson; John P Foreyt; James O Hill; Dace L Trence; Mara Z Vitolins Journal: Obesity (Silver Spring) Date: 2009-01-29 Impact factor: 5.002
Authors: Kim T Mueser; Patrick W Corrigan; David W Hilton; Beth Tanzman; Annette Schaub; Susan Gingerich; Susan M Essock; Nick Tarrier; Bodie Morey; Suzanne Vogel-Scibilia; Marvin I Herz Journal: Psychiatr Serv Date: 2002-10 Impact factor: 3.084
Authors: Carly Lupton-Smith; Elizabeth A Stuart; Emma E McGinty; Arlene T Dalcin; Gerald J Jerome; Nae-Yuh Wang; Gail L Daumit Journal: Front Psychiatry Date: 2022-02-03 Impact factor: 4.157